Provided by Tiger Trade Technology Pte. Ltd.

TYK MEDICINES-B

2.990
+0.31011.57%
Volume:3.61M
Turnover:9.97M
Market Cap:1.14B
PE:-3.20
High:2.990
Open:2.755
Low:2.515
Close:2.680
52wk High:22.560
52wk Low:2.515
Shares:380.07M
HK Float Shares:375.46M
Volume Ratio:1.56
T/O Rate:0.96%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.935
ROE:-70.66%
ROA:-28.19%
PB:3.73
PE(LYR):-3.20
PS:9090.12

Loading ...

TYK Medicines Announces Extraordinary General Meeting

Reuters
·
Jun 29

TYK Medicines Sets 10–15 July 2026 Book Closure to Determine EGM Voting Entitlements

Bulletin Express
·
Jun 24

TYK Medicines shareholders pass Articles of Association amendments at AGM

Reuters
·
Jun 23

TYK Medicines Keeps Share Capital Steady at 380.07 Million H Shares in May; Public Float Meets 25% Rule

Bulletin Express
·
Jun 02

Major Breakthrough at ASCO 2026: TYK MEDICINES-B's Edotinib Achieves 95.5% Intracranial Objective Response Rate, Leading the Frontline Treatment for EGFR Lung Cancer Brain Metastases

Stock News
·
Jun 01

TYK Medicines reports superior interim Phase II data for asandeutertinib versus osimertinib in first-line EGFR-mutant NSCLC with brain metastases

Bulletin Express
·
May 31

Key Phase II ESAONA Study Results for TYK MEDICINES-B's (02410) TY-9591 in First-Line NSCLC Brain Metastases Presented as Late-Breaking Abstract at 2026 ASCO

Stock News
·
May 31

TYK Medicines says Phase II study shows asandeutertinib beats osimertinib on intracranial response in EGFR-mutant NSCLC with brain metastases

Reuters
·
May 31

TYK Medicines Releases 2025 AGM Agenda Covering Profit Distribution, Share Mandates and Board Re-election

Bulletin Express
·
May 22

TYK Medicines to Seek 20% Share Issue Mandate, RMB300 Million Bank Lines and No-Dividend Plan at 23 June AGM

Bulletin Express
·
May 22

Insiders Could Have Profited By Holding onto TYK Medicines Shares Despite 12% Drop

Simply Wall St.
·
May 14

TYK Medicines Posts Stable Share Capital and Maintains Public Float in April 2026 Monthly Return

Bulletin Express
·
May 06

TYK Medicines-B 2025年研发推进加速,亏损收窄至3.06亿元,净资产维持正值

Bulletin Express
·
Apr 29

TYK Medicines publishes 2025 annual report

Reuters
·
Apr 29

TYK MEDICINES-B's (02410) Self-Developed TY-3002 Monotherapy Demonstrates Outstanding Weight Loss Efficacy, Pioneering Next-Generation Oral GLP-1R Small Molecule Innovation

Stock News
·
Apr 16

TYK Medicines Converts 4.61 Million Unlisted Shares Into H Shares, Registered Capital Rises to RMB 380.07 Million

Bulletin Express
·
Apr 08

TYK Medicines Completes 4.61 Million-Share Conversion to H Shares, Expanding Registered Capital to 380.07 Million

Bulletin Express
·
Apr 02

Stock Track | TYK MEDICINES-B Soars 7.26% Intraday on Strong Annual Results and Upcoming AACR Presentation

Stock Track
·
Apr 01

TYK MEDICINES-B Shares Surge Over 7% Following Annual Report and Key AACR Presentation Announcement

Stock News
·
Apr 01

TYK Medicines' Loss Narrows in 2025

MT Newswires Live
·
Mar 31